Geode Capital Management LLC Invests $27,000 in Dogwood Therapeutics, Inc. (NASDAQ:DWTX)

Geode Capital Management LLC acquired a new stake in Dogwood Therapeutics, Inc. (NASDAQ:DWTX) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 10,933 shares of the company’s stock, valued at approximately $27,000. Geode Capital Management LLC owned approximately 0.82% of Dogwood Therapeutics as of its most recent SEC filing.

Analysts Set New Price Targets

Separately, HC Wainwright raised shares of Dogwood Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 target price for the company in a report on Wednesday, April 23rd.

Dogwood Therapeutics Price Performance

Shares of Dogwood Therapeutics stock opened at $4.82 on Tuesday. The company’s 50 day moving average price is $5.27 and its two-hundred day moving average price is $4.91. The firm has a market capitalization of $9.21 million, a P/E ratio of -0.74 and a beta of 1.99. Dogwood Therapeutics, Inc. has a fifty-two week low of $1.62 and a fifty-two week high of $29.28.

Dogwood Therapeutics (NASDAQ:DWTX) last released its quarterly earnings data on Monday, March 31st. The company reported ($6.29) earnings per share for the quarter, missing the consensus estimate of ($1.49) by ($4.80). On average, analysts expect that Dogwood Therapeutics, Inc. will post -6.43 earnings per share for the current year.

About Dogwood Therapeutics

Dogwood Therapeutics, Inc is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia.